IL-1RA suppresses esophageal cancer cell growth by blocking IL-1α

被引:16
|
作者
Chen, Sui [1 ]
Shen, Zhimin [1 ]
Liu, Zhun [1 ]
Gao, Lei [1 ]
Han, Ziyang [1 ]
Yu, Shaobin [1 ]
Kang, Mingqiang [1 ,2 ,3 ]
机构
[1] Fujian Med Univ, Union Hosp, Dept Thorac Surg, Fuzhou, Fujian, Peoples R China
[2] Fujian Med Univ, Minist Educ, Gastrointestinal Canc, Key Lab, Fuzhou, Fujian, Peoples R China
[3] Fujian Med Univ, Fujian Key Lab Tumor Microbiol, Fuzhou, Fujian, Peoples R China
关键词
esophageal cancer; IL-1RA; VEGF; INTERLEUKIN-1-ALPHA; INFLAMMATION;
D O I
10.1002/jcla.22903
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background Interleukin-1 promotes tumor angiogenesis through VEGF production. The interleukin-1 receptor antagonist can suppress tumors by blocking this effect. Methods Immunohistochemistry, WB, and gene sequencing were used to analyze the expression of IL-1RA in esophageal cancer patients. WB was used to detect the expression of IL-1RA and interleukin-1 alpha in esophageal cancer cells. Stable ESCC cell models overexpressing the IL-1RA were constructed. Their cell functions were tested, and their effects on VEGF were examined. Results IL-1RA is downregulated in primary EC tumors, and this downregulation of IL-1RA is closely related to TNM staging and survival prognosis. The overexpression of IL-1RA increased the proliferation of KYSE410 EC cells, which have a high level of IL-1 alpha expression. Overexpression of IL-1RA in KYSE410 cells promotes a decrease in the expression of VEGF-A. However, IL-1RA expression did not cause any changes in EC9706 cells with low IL-1 alpha expression. Conclusion IL-1RA acts as a tumor suppressor, and its deletion promotes tumor progression by increasing VEGF-A expression in ESCC.
引用
收藏
页数:7
相关论文
共 50 条
  • [22] USE OF THE IL-1 RECEPTOR ANTAGONIST (IL-1RA) IN IL-2-TREATED MICE
    NUMEROF, RP
    SIPE, JD
    ZHANG, Y
    DINARELLO, CA
    MIER, JW
    LYMPHOKINE RESEARCH, 1990, 9 (04): : 612 - 612
  • [23] Interleukin-1 (IL-1α and IL-1β) and its receptors (IL-1RI, IL-1RII, and IL-1Ra) in prostate carcinoma
    Ricote, M
    García-Tuñón, I
    Bethencourt, FR
    Fraile, B
    Paniagua, R
    Royuela, M
    CANCER, 2004, 100 (07) : 1388 - 1396
  • [24] IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines
    Tahtinen, Siri
    Tong, Ann-Jay
    Himmels, Patricia
    Oh, Jaehak
    Paler-Martinez, Andres
    Kim, Leesun
    Wichner, Sara
    Oei, Yoko
    McCarron, Mark J.
    Freund, Emily C.
    Amir, Zhainib Adel
    de la Cruz, Cecile C.
    Haley, Benjamin
    Blanchette, Craig
    Schartner, Jill M.
    Ye, Weilan
    Yadav, Mahesh
    Sahin, Ugur
    Delamarre, Lelia
    Mellman, Ira
    NATURE IMMUNOLOGY, 2022, 23 (04) : 532 - +
  • [25] A truncated form of the soluble IL-1 receptor type I which binds IL-1ra but not IL-1 alpha or IL-1 beta.
    Caffes, P
    Anderson, LJ
    Vigers, GPA
    Brandhuber, BJ
    PROTEIN ENGINEERING, 1997, 10 : 81 - 81
  • [26] DIFFERENTIAL EXPRESSION OF IL-1 AND IL-1 RECEPTOR ANTAGONIST (IL-1RA) IN NORMAL AND LPS-TREATED RABBITS
    MONSACCHI, L
    CASINIRAGGI, V
    PIZARRO, TT
    COMINELLI, F
    FASEB JOURNAL, 1994, 8 (05): : A997 - A997
  • [27] DIFFERENTIAL EXPRESSION OF IL-1 AND IL-1 RECEPTOR ANTAGONIST (IL-1RA) IN NORMAL AND LPS-TREATED RABBITS
    MONSACCHI, L
    CASINIRAGGI, V
    PIZARRO, TT
    COMINELLI, F
    GASTROENTEROLOGY, 1994, 106 (04) : A738 - A738
  • [28] INTERLEUKIN-1 (IL-1) AND INTERLEUKIN-1 RECEPTOR ANTAGONIST (IL-1RA)
    CONTI, P
    ANNALES DE MEDECINE INTERNE, 1991, 142 (07): : 521 - 525
  • [29] Characterization of type II intracellular IL-1 receptor antagonist (IL-1ra3): a depot IL-1ra
    Muzio, M
    Polentarutti, N
    Facchetti, F
    Peri, G
    Doni, A
    Sironi, M
    Transidico, P
    Salmona, M
    Introna, M
    Mantovani, A
    EUROPEAN JOURNAL OF IMMUNOLOGY, 1999, 29 (03) : 781 - 788
  • [30] Imbalance production between interleukin-1β (IL-1β) and IL-1 receptor antagonist (IL-1Ra) in bronchial asthma
    Mao, XQ
    Kawai, M
    Yamashita, T
    Enomoto, T
    Dake, Y
    Sasaki, S
    Kataoka, Y
    Fukuzumi, T
    Endo, K
    Sano, H
    Aoki, T
    Kurimoto, F
    Adra, CN
    Shirakawa, T
    Hopkin, JM
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2000, 276 (02) : 607 - 612